Feature | Sudden Cardiac Arrest | October 07, 2019

Sudden Cardiac Arrest Patient Walks to Ambulance Thanks to Wearable Defibrillator

LifeVest shocks Cleveland man and saves his life at home, prescribed wearable defibrillator just three days earlier

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

October 7, 2019 — Glynn Crawford was hospitalized at University Hospitals Ahuja Medical Center in late June/early July for chronic abdominal issues associated with his irregular heartbeat (paroxysmal atrial fibrillation) and weakened heart muscle (non-ischemic cardiomyopathy). After prescribing medications, UH Harrington Heart and Vascular Institute cardiologist Barbara Williams, M.D., determined Crawford had increased risk of sudden cardiac arrest (SCA). She recommended a Zoll LifeVest wearable defibrillator, which is designed to continuously monitor the wearer’s heart, detect life-threatening rapid heart rhythms and automatically deliver a treatment shock to restore a normal rhythm. The device also alerts bystanders when a shock has been delivered so they can contact emergency medical personnel.

Just three days after leaving the hospital, the LifeVest saved the 68-year-old’s life when he was lying in bed at home in Warrensville Heights, Ohio. “The next thing I knew, I woke up with my wife telling me that the vest had shocked my heart back into rhythm,” said Crawford. “The alarm had alerted her to what was happening and she called 911. When they arrived, I was able to walk outside to the ambulance myself.”

The following day, a permanent defibrillator was implanted in his chest. 

“Very grateful, I can’t even begin to explain it,” said Crawford. “I wouldn’t be alive without it, because I didn’t realize that I was as sick as I was at the time.”

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

The Zoll Lifevest is worn under the patient's clothes as a precaution against sudden cardiac arrest (SCA).

SCA occurs when a failure of the heart’s electrical system triggers a dangerously fast heartbeat - so fast that it causes the heart to quiver or shake instead of pumping blood to the body and brain. Patients have an increased risk of SCA following a cardiac event, such as a heart attack or new diagnosis of heart failure.

“Glynn is the perfect example of a good candidate for LifeVest,” said Mauricio Arruda, M.D., director, clinical electrophysiology and pacing at UH Cleveland Medical Center. “Another potential benefit of LifeVest would be to someone after a heart attack resulting in decreased heart function who undergoes intervention to re-open a blocked coronary artery. Such a patient may be at risk of sudden death for a period of time.”

Arruda says it is important for heart patients to have awareness about devices like LifeVest. “These devices are potentially under-prescribed and underutilized, particularly at centers with limited education on this issue or few heart rhythm specialists,” he explained.

Today, Crawford’s abdominal issues have resolved and his medications are working well to manage his cardiovascular conditions.

October is SCA Awareness Month. According to the Sudden Cardiac Arrest Foundation, nearly 350,000 people experience out-of-hospital cardiac arrest every year and in more than half of those instances there is no witness.

 

Related SCA Content:

Wearable Defibrillator Offers a Bridge Therapy

VIDEO: Should Student Athletes be Screened for Sudden Cardiac Arrest? — Interview With Malissa Wood, M.D.

Survey Shows Majority of Americans Unaware of Effective Treatment Options to Protect Against Sudden Cardiac Arrest

 

Related Content

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...